COLL (Collegium Corp) יחס שווי שוק לשווי בספרים

Collegium Pharmaceutical (COLL) revenues are based on the sale of proprietary pain management products through pharmacy channels. Market fluctuations in the share price reflect the current 2.42 indicator. Quotes are supported by expansion via the BDSI deal, rising demand for key prescription products, active share buybacks, and high operating profitability that ensures a steady flow of liquidity.

The diversified pain management drug portfolio of Collegium Pharmaceutical (COLL) ensures asset stability, which is clearly reflected in the P/B ratio history. This indicator is calculated as the ratio of the company's market value to its net asset value, allowing investors to instantly identify a fundamental discount or business overvaluation, separating stable enterprises from speculative securities during periods of volatility.